Picture of Integer Holdings logo

ITGR — Integer Holdings News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedLarge CapHigh Flyer

Integer Holdings Q2 sales fall 2.6%; KKR to buy company for $5.7 billion

Integer Holdings Q2 sales fall 2.6%; KKR to buy company for $5.7 billion


Overview

  • U.S. medical device maker's Q2 sales fell 2.6% but beat analyst expectations

  • Adjusted EPS for Q2 rose 3% and beat analyst expectations

  • Company to be acquired by KKR in $5.7 bln all-cash deal; outlook withdrawn


Outlook

  • Integer is withdrawing its previously issued financial outlook due to pending acquisition by KKR


Result Drivers

  • CARDIO & VASCULAR WEAKNESS - Co said Cardio & Vascular sales fell 2% due to the impact from two new Electrophysiology products

  • OTHER MARKETS DECLINE - Co attributed 43% drop in Other Markets sales to exit from Portable Medical market

  • RESTRUCTURING AND IMPAIRMENT COSTS - Co recorded fixed asset impairment charges and restructuring expenses, affecting operating income


Company press release: ID:nGNX7fVlXS


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Sales

Beat

$464 mln

$450.50 mln (9 Analysts)

Q2 Adjusted EPS

Beat

$1.60

$1.41 (8 Analysts)

Q2 EPS

$0.69

Q2 Adjusted Net Income

Beat

$55 mln

$48.17 mln (7 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

  • Wall Street's median 12-month price target for Integer Holdings Corp is $98.00, about 19.1% below its July 31 closing price of $121.21

  • The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 14 three months ago


Reuters Recommended Reads

  • July 31 - IRadimed Q2 profit rises on record monitor bookings

  • Aug 3 - AstraZeneca investors baulk at $400 billion Bristol Myers talks

  • July 31 - AbbVie trims 2026 profit view on Apogee deal, tops second-quarter estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Integer Holdings

See all news